Big R&D Investment Trend as Mid-Cap Biotechs Push to Get Drugs to Market
Biotech firms eager to push drug candidates through clinical trials prompted an overall increase in R&D expenditure of 20% in just a year, states research and consulting firm GlobalData.
GlobalData’s new report*, which compares the competitive position of 15 innovative mid-cap biotech companies** on 20 financial metrics, states that the peer group R&D spend for Q3 2012 reached US$746.8m, climbing from US$621.1m in Q3 2011.
“Oncology is the main focus of biotech R&D activities,” says Adam Dion, GlobalData’s Analyst covering Healthcare Industry Dynamics, “which is driving peer group R&D expenses higher.”
Regeneron was the firm with the highest R&D expenditure for Q3 2012, with an outlay of US$158m. According to the report, Regeneron’s R&D spend has increased steadily each quarter since Q3 2011, when the total stood at US$128m.
“Biotech companies are becoming increasingly more successful at developing innovative therapies,” says Dion. “However, our research has found that the high cost of bringing these therapies to market continues to erode corporate profitability.”
In terms of percentages, ViroPharma displayed the biggest year-to-year drop in R&D expenditure. The company’s R&D spending plummeted 28% year-to-year, from US$22.9m in Q3 2011 to US$16.5m in Q3 2012.The decrease in ViroPharma’s R&D spend was caused by the Food and Drug Administration’s suspension of the company’s clinical trials of its flagship product Cinryze due to safety concerns.
“The FDA put a hold on two of the company’s Phase II clinical studies when trials revealed elevated antibody levels detected in the treatment arm of the study,” explains Dion. “These concerns have since been addressed and, with FDA approval, the firm resumed the trials in September of last year.”
As defined by a proprietary ratings system based on a number of financial metrics including revenue, sales growth and cost containment, GlobalData identified Regeneron as the peer group benchmark leader in the third quarter, overtaking the Q2 2012 number one, Alexion.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
